請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56875完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃德富(Tur-Fu Huang) | |
| dc.contributor.author | Po-Yen Chang | en |
| dc.contributor.author | 張博雁 | zh_TW |
| dc.date.accessioned | 2021-06-16T06:30:37Z | - |
| dc.date.available | 2014-10-15 | |
| dc.date.copyright | 2014-10-15 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-07 | |
| dc.identifier.citation | Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006 Sep;81(9):1241-57.
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008 May 15;22(10):1276-312. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990 Aug;4(11):2868-80. Arthur WT, Noren NK, Burridge K. Regulation of Rho family GTPases by cell-cell and cell-matrix adhesion. Biol Res. 2002;35(2):239-46. Anthis NJ, Wegener KL, Critchley DR, Campbell ID. Structural diversity in integrin/talin interactions. Structure. 2010 Dec 8;18(12):1654-66. Bowen Pope DF, Hart CE, Seifert RA. Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. J Biol Chem. 1989 Feb 15;264(5):2502-8. Bendeck MP, Irvin C, Reidy M, Smith L, Mulholland D, Horton M, Giachelli CM. Smooth muscle cell matrix metalloproteinase production is stimulated via alpha(v)beta(3) integrin. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1467-72. Beviglia L, Stewart GJ, Niewiarowski S. Effect of four disintegrins on the adhesive and metastatic properties of B16F10 melanoma cells in a murine model. Oncol Res. 1995;7(1):7-20. Bronson RA, Gailit J, Bronson S, Oula L. Echistatin, a disintegrin, inhibits sperm-oolemmal adhesion but not oocyte penetration. Fertil Steril. 1995 Aug;64(2):414-20. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994 Dec;28(12):1815-20. Bougie DW, Rasmussen M, Zhu J, Aster RH. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood. 2012 Jun 28;119(26):6317-25. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994 Apr 22;264(5158):569-71. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008 Feb;49(2):255-9. Coleen A. McNamara, Ian J. Sarembock, Brian G. Bachhuber, George A. Stouffer, Michael Ragosta, William Barry, Lawrence W. Gimple, Eric R. Powers, Gary K. Owens. Thrombin and Vascular Smooth Muscle Cell Proliferation: Implications for Atherosclerosis and Restenosis. Semin Thromb Hemost 1996; 22(2): 139-144 Clyman RI, McDonald KA, Kramer RH. Integrin receptors on aortic smooth muscle cells mediate adhesion to fibronectin, laminin, and collagen. Circ Res. 1990 Jul;67(1):175-86. Calvete JJ, Marcinkiewicz C, Monleón D, Esteve V, Celda B, Juárez P, Sanz L. Snake venom disintegrins: evolution of structure and function. Toxicon. 2005 Jun 15;45(8):1063-74. Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Blood Coagul Fibrinolysis. 2008 Sep;19(6):557-67. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983 Jul;72(1):325-38. Cox EA, Sastry SK, Huttenlocher A. Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases. Mol Biol Cell. 2001 Feb;12(2):265-77. Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol. 2001 Jun;3(6):580-6. Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev. 2012 May 21;41(10):3742-52. Calderwood DA, Ginsberg MH. Talin forges the links between integrins and actin. Nat Cell Biol. 2003 Aug;5(8):694-7. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011 Apr 26;123 (16):1745-56. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. Jul 15, 2012; 95(2): 156–164. Danen EH, van Rheenen J, Franken W, Huveneers S, Sonneveld P, Jalink K, Sonnenberg A. Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol. 2005 May 9;169(3):515-26. Datta A, Huber F, Boettiger D. Phosphorylation of beta3 integrin controls ligand binding strength. J Biol Chem. 2002 Feb 8;277(6):3943-9. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996 Dec 6;274(5293):1664-72. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res. 2001 Dec 7;89(12):1104-10. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003 Oct 7;108(14):1701-6. Epub 2003 Sep 22. Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM. Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol. 2010;26:315-33. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996 Feb 9;84(3):345-57. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007 Mar 16;100(5):607-21. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, Niewiarowski S. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med. 1990 Nov;195(2):168-71. Heldin CH, Ostman A, Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998 Aug 19;1378(1):F79-113. Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999 Jun;126(14):3047-55. Heldin CH. Structural and functional studies on platelet-derived growth factor. EMBO J. Dec 1992; 11(12): 4251–4259. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys. 2002 Feb 15;398(2):284-90. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003 Oct;130(20):4769-84. Heidaran MA, Pierce JH, Jensen RA, Matsui T, Aaronson SA. Chimeric alpha- and beta-platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the alpha-PDGF receptor that determine PDGF-AA binding specificity. J Biol Chem. 1990 Nov 5;265(31):18741-4. Humphries MJ. Integrin structure. Biochem Soc Trans. 2000;28(4):311-39. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002 Sep 20;110(6):673-87. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J Biol Chem. 1987 Nov 25;262(33):16157-63. Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem. 1992 Nov 27;35(24):4640-2. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci. 2009 Apr 15;122(Pt 8):1059-69. Hsu CC, Chuang WJ, Chang CH, Tseng YL, Peng HC, Huang TF. Improvements in endotoxemic syndromes using a disintegrin, rhodostomin, through integrin αvβ3-dependent pathway. J Thromb Haemost. 2011 Mar;9(3):593-602. Hoffmann R, Mintz G S. Coronary in-stent restenosis — predictors, treatment and prevention. European Heart Journal 2000;21, 1739–1749 Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993 May;91(5):2268-74. Imanaka-Yoshida K, Matsuura R, Isaka N, Nakano T, Sakakura T, Yoshida T. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch. 2001 Aug;439(2):185-90. Ishigaki T, Imanaka-Yoshida K, Shimojo N, Matsushima S, Taki W, Yoshida T. Tenascin-C enhances crosstalk signaling of integrin αvβ3/PDGFR-β complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J Cell Physiol. 2011 Oct;226(10):2617-24. Juliano D, Wang Y, Marcinkiewicz C, Rosenthal LA, Stewart GJ, Niewiarowski S. Disintegrin interaction with alpha V beta 3 integrin on human umbilical vein endothelial cells: expression of ligand-induced binding site on beta 3 subunit. Exp Cell Res. 1996 May 25;225(1):132-42. Janat MF, Argraves WS, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor beta1 and by platelet-derived growth factor-BB. J Cell Physiol. 1992 Jun;151(3):588-95. Kirchengast M, Münter K. Endothelin and restenosis. Cardiovasc Res. 1998 Sep;39(3):550-5. Karlsson L, Lindahl P, Heath JK, Betsholtz C. Abnormal gastrointestinal development in PDGF-A and PDGFR-(alpha) deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Development. 2000 Aug;127(16):3457-66. Kokubo T, Uchida H, Choi ET. Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J Vasc Surg. 2007 Jun;45 Suppl A:A33-8. Knudsen KA, Tuszynski GP, Huang TF, Niewiarowski S. Trigramin, an RGD-containing peptide from snake venom, inhibits cell-substratum adhesion of human melanoma cells. Exp Cell Res. 1988 Nov;179(1):42-9. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997 Apr 21;137(2):481-92. Kundra V, Escobedo JA, Kazlauskas A, Kim HK, Rhee SG., Williams LT, and Zetter BR. 1994. Regulation of chemotaxis by the platelet-derived growth factor receptor-β. Nature. 367(6462):474-6. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680-5. Louis SF, Zahradka P. Vascular smooth muscle cell motility: From migration to invasion. Exp Clin Cardiol. 2010 Winter;15(4):e75-85. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 1996 Dec;28(7):1643-51. Laszlo Denes, Laszlo Entz, Veronika Jancsik. Restenosis and Therapy. Int J Vasc Med. 2012; 2012: 406236. Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res. 2001 Dec;52(3):372-86. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990 Nov;111(5 Pt 1):2149-58. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11. McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M, Barry W, Gimple LW, Powers ER, Owens GK. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost. 1996;22(2):139-44. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site. Blood. 1997 Aug 15;90(4):1565-75. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000 Mar 15;35(4):915-21. Newby AC, Zaltsman AB. 2000. Molecular mechanisms in intimal hyperplasia. J Pathol. 190(3):300-9. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2835-40. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004. 84(3):767-801. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995. 75(3):487-517. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995 Sep 1;269(5228):1270-2. Pardee AB. G1 events and regulation of cell proliferation. Science. 1989 Nov 3;246(4930):603-8. Page K, Li J, Hodge JA, Liu PT, Vanden Hoek TL, Becker LB, Pestell RG, Rosner MR, Hershenson MB. Characterization of a Rac1 signaling pathway to cyclin D(1) expression in airway smooth muscle cells. J Biol Chem. 1999 Jul 30;274(31):22065-71. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda). 2009 Dec;24:342-56. Patsenker E, Stickel F. Role of integrins in fibrosing liver diseases. Am J Physiol Gastrointest Liver Physiol. 2011 Sep;301(3):G425-34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801-9. Ross R, Raines EW and Bowen Pope DF. 1986. The biology of platelet derived growth factor. Cell. 46(2):155-69. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986;44:517–8 Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity. 2011 Oct 28;35(4):445-55. Sherif F Louis, Peter Zahradka. Vascular smooth muscle cell motility: From migration to invasion. Exp Clin Cardiol. 2010 Dec; 15(4): 75-85. Shebuski RJ, Ramjit DR, Bencen GH, Polokoff MA. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. J Biol Chem. 1989 Dec 25;264(36):21550-6. Sheu JR, Lin CH, Huang TF. Triflavin, an antiplatelet peptide, inhibits tumor cell-extracellular matrix adhesion through an arginine-glycine-aspartic acid-dependent mechanism. J Lab Clin Med. 1994 Feb;123(2):256-63. Scarborough RM. Development of eptifibatide. Am Heart J. 1999 Dec;138(6 Pt 1):1093-104. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993 Jan 15;268(2):1066-73. Sohn YD, Cho KS, Sun SA, Sung HJ, Kwak KW, Hong SY, Kim DS, Chung KH. Suppressive effect and mechanism of saxatilin, a disintegrin from Korean snake (Gloydius saxatilis), in vascular smooth muscle cells. Toxicon. 2008 Sep 1;52(3):474-80. Schwartz SM. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest. 1997 Dec 1;100(11 Suppl):S87-9. Vaziri C, Faller DV. Repression of platelet-derived growth factor beta-receptor expression by mitogenic growth factors and transforming oncogenes in murine 3T3 fibroblasts. Mol Cell Biol. Mar 1995; 15(3): 1244–1253. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science. 1989 Mar24;243 (4898): 1564-1570 Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta. 2010 Aug;1806(1):122-30. White DP, Caswell PT, Norman JC. alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J Cell Biol. 2007 May 7;177(3):515-25. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol. 2004 Feb;6(2):154-61. Watts KL, Cottrell E, Hoban PR, Spiteri MA. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir Res. 2006 Jun 15;7:88. Zhu J, Zhu J, Negri A, Provasi D, Filizola M, Coller BS, Springer TA. Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood. 2010 Dec 2;116(23):5050-9. Zhu J, Choi WS, McCoy JG, Negri A, Zhu J, Naini S, Li J, Shen M, Huang W, Bougie D, Rasmussen M, Aster R, Thomas CJ, Filizola M, Springer TA, Coller BS. Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDAS. Sci Transl Med. 2012 Mar 14;4(125):125ra32. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56875 | - |
| dc.description.abstract | 心導管冠狀動脈血管氣球擴張術 (percutaneous coronary intervention，PTCA) 後所造成的血管再狹窄 (restenosis) 與血小板活化產生血栓以及血管平滑肌細胞異常地過度生長與移行有關。血小板衍生因子 (platelet-derived growth factor，PDGF) 在這過程中被認為是一個重要的刺激因子。Echispydin是一種從來自 Echis pyramidium 的蛇毒蛋白中純化出的dimeric disintegrin, 在本研究中證實在體外可濃度相關地抑制由collagen，thrombin以及U46619所以引發的人類血小板凝集。此外，藉由受體結合位的競爭實驗中發現 Echispydin 與 GPIIb/IIIa 拮抗劑 7E3 在血小板上有類似的結合部位而與10E5在不同的部位，並且在大鼠平滑肌細胞中可拮抗 integrin β3 的 mAb F11有競爭結合位的現象，因此證明 Echispydin 不只作用在血小板 GPIIb/IIIa 上，也會結合到老鼠平滑肌細胞上的αvβ3 integrin。我們進而觀察到 Echispydin 在老鼠平滑肌細胞上可濃度相關地抑制 PDGF 與 10% FBS 所引起的血管平滑肌細胞增生與移行，且在PDGF的組別中抑制效果明顯大於10% FBS的組別，也藉由乳酸脫氫酶釋放實驗 (LDH release assay) 確認 Echispydin 的這些作用並非來自於它的細胞毒性。此外，我們利用PI染色來分析 Echispydin 對細胞週期分布的影響，觀察到在 PDGF 組隨著 Echispydin 劑量上升，有輕微的 sub-G1 累積並且有 G1/S phase transition 停止的現象。由於在 PDGF 組別中發現 Echispydin 造成明顯的細胞型態改變與細胞脫離，所以我們進一步研究 Echispydin 對於 PDGF 所引起之 F-actin 形成之影響，發現 Echispydin 會抑制 PDGF 所引起之 F-actin 的形成也發現 Echispydin 會抑制平滑肌細胞貼附到 fibrinogen 與 fibronectin 上。接著我們研究 Echispydin 對於 PDGF 所引起的訊號傳遞之影響，結果顯示 Echispydin 會抑制 PDGF 引起的 PDGFRβ、PLCγ1、FAK、c-Src 與 MAPKs (p38、ERK1/2、JNK1/2) 在大鼠主動脈平滑肌細胞的磷酸化，但不影響 PI3K 和 Akt 的磷酸化。此外，Echispydin 也會抑制 PDGF 刺激後和細胞週期相關的 Cyclin D1/2 以及抑制和細胞骨架相關的 small GTPase, Rho的活化。綜合以上結果我們認為 Echispydin 抑制 PDGFRβ 下游的訊息傳導的原因是藉由結合到 αvβ3 integrin 上而抑制了 PDGFRβ 與 αvβ3 integrin 間的 crosstalk。基於 Echispydin 具有抗血小板凝集與抑制平滑肌細胞生長與移行的能力，我們認為其有治療動脈損傷後血管再狹窄的療效潛力。 | zh_TW |
| dc.description.abstract | Restenosis caused by percutaneous coronary intervention (PTCA) is related to thrombosis induced by platelet activation and abnormal growth and migration of vascular smooth muscle cells. Platelet-derived growth factor (PDGF) is considered as an essential stimulation factor in this process. Echispydin is a dimeric disintegrin purified from the snake venom of Echis pyramidium and in this study, it concentration-dependently inhibited human platelet aggregation induced by collagen, thrombin, or U46619 in vitro. According to the binding analysis, Echispydin and 7E3 may bind to a common epitope which is different from that of 10E5 on platelet, and Echispydin decreased the binding of mAb F11 raised against β3 integrin on rat arotic smooth muscle cell, confirming that Echispydin not only binds to GPIIb/IIIa on platelet but also binds to integrin αvβ3 on rat arotic smooth muscle cell. Echispydin inhibited PDGF and 10% FBS induced proliferation and migration of smooth muscle cell in a concentration-dependent manner and the inhibitory effect of Echispydin on PDGF induced condition was more pronounced than 10% FBS induced condition. We also confirmed that these effects are not due to its cytotoxicity by LDH release assay. Moreover, we analyzed the effect of Echispydin on cell cycle progression by PI staining and the results indicated that Echispydin treated cells under PDGF stimulation exhibited a slightly increase of sub-G1 phase and an arrest of G1/S phase transition in a concentration-dependent manner. Since we observed that Echispydin caused significant morphological change and cell detachment on smooth muscle cell under PDGF stimulation, so we further investigated the effect of Echispydin on PDGF-induced F-actin formation, and results showed that Echispydin inhibited PDGF-induced the formation of F-actin. Additionally, it also inhibited smooth muscle cell adhesion to fibrinogen and fibronectin. Echispydin inhibited PDGF-induced phosphorylation of PDGFRβ, PLCγ1, FAK, c-Src and MAPKs (p38, ERK1/2, JNK1/2) in rat aortic smooth muscle cells, but did not affect the phosphorylation of PI3K and Akt. Furthermore, Echispydin also inhibited cell cycle related molecules, Cyclin D1/2 and inhibited cytoskeleton-related small GTPase, Rho activation after PDGF stimulation. These data suggest that Echispydin inhibited PDGFRβ downstream signaling by binding to αvβ3 integrin and then inhibited crosstalk between PDGFRβ and αvβ3 integrin. Therefore, we consider Echispydin as a potent reagent for the prevention of restenosis based on its anti-platelet activity and inhibitory effects on proliferation and migration of smooth muscle cell. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T06:30:37Z (GMT). No. of bitstreams: 1 ntu-103-R01443008-1.pdf: 11413881 bytes, checksum: 9585fb770bc7ce422c956abb6795867f (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 中文摘要…………………………………………………………i
英文摘要………………………………………………………iii 縮寫表……………………………………………………………v 第一章 Introduction……………………………………………… 1 1.1 Restenosis…………………………………………………… 1 1.2 Vascular smooth muscle cells ……………………………2 1.2-1 Migration of VSMC………………………………………3 1.2-2 Mechanisms of VSMC Proliferation: The Cell Cycle…4 1.3 Platelet-derived growth factor (PDGF), receptor (PDGFR) and PDGF-induced signal transduction…………………………5 1.4 Integrins……………………………………………………8 1.4-1 αvβ3 integrin……………………………………9 1.5 Disintegrin………………………………………………10 1.6 GPIIb/IIIa inhibitors…………………………………11 1.6-1 RGD mimetic drugs designed from snake venom disintegrins : Eptifibatide and Tirofiban……………11 1.6-2 GPIIb/IIIa and αvβ3 integrin antagonist : Monoclonal Antibody Abciximab……………………………13 1.7 Integrin and Growth Factor Receptor Crosstalk……14 1.7-1 Crosstalk between Integrin αvβ3 and PDGFR-β…14 1.8 Role of small GTPases in vascular smooth muscle cell…15 1.9 Aims of this thesis……………………………………………17 第二章 Materials and methods…………………………………28 第三章 Results…………………………………………………… 43 3.1 Purification of Echispydin from Echis pyramidium snake venom …………………………………………………………………43 3.2 Determination of purity and molecular weight of Echispydin……………………………………………………………44 3.3 Effect of Echispydin on platelet aggregation…………44 3.4 Flow cytometric analysis of Echispydin binding to platelets……………………………………………………………45 3.5 Flow cytometric analysis of Echispydin binding to RASMC ……………………………………………………………46 3.6 Echispydin inhibited PDGF-BB and serum induced RASMC growth…………………………………………………………47 3.7 Echispydin inhibited PDGF induced DNA synthesis in RASMC …………………………………………………………48 3.8 Echispydin does not cause LDH release in RASMCs……48 3.9 Effect of Echispydin on RASMC cell cycle progression…49 3.10 Echispydin reduced serum and PDGF-induced RASMC migration……………………………………………………50 3.11 Echispydin inhibited RASMC adhesion to fibrinogen and fibronection……………………………………………………51 3.12 Echispydin inhibited the formation of F-actin in VSMC………………………………………………………………52 3.13 Echispydin inhibited PDGF-induced PDGFRβ and PLCγ1 phosphorylation………………………………………………52 3.14 Echispydin inhibited PDGF-induced FAK and c-Src phosphorylation………………………………………………53 3.15 Echispydin inhibited PDGF-induced ERK1/2, p-38 and JNK1/2 phosphorylation…………………………………………54 3.16 Echispydin inhibited PDGF-induced Rho activation……54 3.17 Echispydin attenuated the expression of Cyclin D1/2…55 3.18 Effect of Echispydin on basal activity of RASMC………55 3.19 Effect of Echispydin on ex vivo mice platelet aggregation…………………………………………………………56 3.20 Effect of Echispydin on bleeding time and platelet counts………………………………………………………………56 第四章 Discussion……………………………………………………88 第五章 Conclusion and perspectives……………………………94 Reference…………………………………………………………… 100 | |
| dc.language.iso | en | |
| dc.subject | Disintegrin | zh_TW |
| dc.subject | 血管平滑肌細胞 | zh_TW |
| dc.subject | 血小板衍生因子 | zh_TW |
| dc.subject | αvβ3 integrin | zh_TW |
| dc.subject | 血管再狹窄 | zh_TW |
| dc.subject | PDGF | en |
| dc.subject | Disintegrin | en |
| dc.subject | Vascular smooth muscle cell | en |
| dc.subject | Restenosis | en |
| dc.subject | αvβ3 integrin | en |
| dc.title | 蛇毒蛋白Echispydin對血管平滑肌細胞增生與移行之抑制作用及機轉之探討 | zh_TW |
| dc.title | The inhibitory effects and action mechanism of Echispydin on proliferation and migration of vascular smooth muscle cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 鄧哲明(Che-Ming Teng),顏茂雄(Mao-Hsiung Yen),楊春茂(Chuen-Mao Yang),吳文彬(Wen-Bin Wu) | |
| dc.subject.keyword | Disintegrin,血管平滑肌細胞,血小板衍生因子,αvβ3 integrin,血管再狹窄, | zh_TW |
| dc.subject.keyword | Disintegrin,Vascular smooth muscle cell,PDGF,αvβ3 integrin,Restenosis, | en |
| dc.relation.page | 110 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 11.15 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。